Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Incorporated reported Q3 2025 results with product revenues, net of $142,342, up from $93,425 a year ago. ARIKAYCE delivered $114,291 (US $73,984; International $40,307), and the newly approved BRINSUPRI contributed $28,051 in its US launch quarter. Operating expenses rose sharply, including a $104,653 increase in the fair value of contingent consideration, leading to an operating loss of $366,005 and a net loss of $370,021. Basic and diluted net loss per share was $1.75 on 211,759 thousand weighted average shares.
Liquidity and capital structure shifted meaningfully. Cash and cash equivalents were $334,764 and marketable securities were $1,345,222 as of September 30, 2025. Long-term debt declined to $539,719 from $1,103,382 as the 0.75% 2028 notes were largely converted and then redeemed, while an amended senior term loan now carries a fixed 9.6% rate and matures in 2029. Shares outstanding were 212,583,015 as of September 30, 2025.
Pipeline and commercialization updates included FDA approval of BRINSUPRI on August 12, 2025 and continued global sales of ARIKAYCE. For the nine months ended September 30, 2025, product revenues, net were $342,580 versus $259,265, while operating cash use was $687,418, reflecting heavier R&D and SG&A to support launches and development.
Insmed Incorporated announced it has furnished a press release detailing its financial results for the third quarter ended September 30, 2025. The company also provided a slide presentation to accompany its conference call.
Both materials are included as Exhibits 99.1 and 99.2. The information is furnished under Item 2.02 and Item 9.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act.
INSMED Inc (INSM) reporting person S. Nicole Schaeffer, Chief People Strategy Officer, completed multiple transactions on 09/12/2025 under a 10b5-1 plan. She exercised 56,520 stock options with a $23.75 exercise price, resulting in ownership of 56,520 shares from the exercise and a reported pre-sale beneficial ownership of 112,981 shares. On the same date she sold a total of 76,520 shares in four separate sell transactions at weighted average prices of $144.6, $145.67, $146.57, and $147.46, leaving her with 36,461 shares beneficially owned following the reported transactions. The sales were effected pursuant to a 10b5-1 trading plan adopted June 13, 2025, and the filing is signed by an attorney-in-fact on behalf of the reporting person.
Melvin Sharoky, M.D., a director of INSMED Inc (INSM), reported multiple transactions on Form 4 reflecting gifts and a market sale. The filing shows gift transactions (Code G) and a sale of 10,000 shares on 09/12/2025 at a weighted average price of $145.39 per share. Following the reported sale and other transactions, the reporting person directly beneficially owns 262,675 shares. The report also discloses indirect holdings through entities Baby Gator LLC and Padonia, LLC and multiple custodial UTMA accounts where the reporting person is custodian.
Insmed, Inc. (INSM) reporting person S. Nicole Schaeffer, Chief People Strategy Officer and director, reported a non-derivative disposition on 09/04/2025. The filing shows a gift (Transaction Code G) of 23,303 common shares at a price of $0, leaving 56,461 shares beneficially owned directly after the transaction. No derivative transactions were reported. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Insmed, Inc. (INSM) Chief Legal Officer Michael A. Smith reported transactions on 09/02/2025. Mr. Smith exercised stock options to acquire 12,780 shares at an exercise price of $30.46 and immediately sold multiple blocks of common stock under a Rule 10b5-1 trading plan. The sales totaled 24,252 shares at weighted average prices ranging from $140.58 to $146.04 per share, reducing his reported beneficial ownership from 79,174 shares to 54,902 shares. All exercised options are currently exercisable and the transactions were effected pursuant to a 10b5-1 plan adopted February 27, 2025.
Martina Flammer, M.D., Chief Medical Officer of Insmed Inc. (INSM), reported multiple option exercises and subsequent open-market sales on 09/02/2025 under a 10b5-1 trading plan. The filing shows the exercise of stock options at strike prices ranging from $17.07 to $34.03, converting options into shares (total option exercises listed include 186,943 underlying shares across multiple option grants). Following exercises, the report lists a series of sales on the same date totaling 209,066 shares sold at weighted-average prices between $140.56 and $146.51, with incremental remaining beneficial ownership reported at 83,111 shares after the transactions. The Form 4 notes the 10b5-1 plan was adopted on February 27, 2025, and includes vesting schedules for each option series.
JPMorgan Chase & Co. filed an amendment to Schedule 13G reporting beneficial ownership of 23,014,584 shares of Insmed Incorporated common stock (CUSIP 457669307), representing 10.8% of the class. The filing breaks down voting and dispositive powers: 20,997,990 shares with sole voting power and 22,971,006 shares with sole dispositive power; smaller amounts are held with shared powers. The filing lists affiliated entities through which holdings are held, including J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA, and various asset management and international affiliates. The filing certifies the shares are held in the ordinary course of business and not for the purpose of influencing control.
Form 144 filed for Insmed, Inc. (INSM) reporting a proposed sale of common stock. The notice lists a proposed sale of 186,648 shares through Merrill Lynch (Washington, DC) with an aggregate market value of $26,935,498 and total shares outstanding of 211,374,786. The shares to be sold were acquired on 09/02/2025 under a stock plan and the payment/settlement date is the same day. The filing also discloses that the reporting person, Martina Flammer, sold 55,564 shares during the past three months for aggregate gross proceeds of $5,190,291 across four transactions dated 06/03/2025 to 08/04/2025. The form includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insmed, Inc. reported a Form 144 notice for the proposed sale of 24,272 common shares through Merrill Lynch on Nasdaq, with an aggregate market value of $3,491,647.00 and an approximate sale date of 09/02/2025. The filing lists multiple stock-plan acquisitions by the seller throughout 2024–2025 totaling 31,272 shares acquired (individual grants dated 07/08/2024, 01/04/2025, 01/06/2025, 01/07/2025, 02/05/2025 and 09/02/2025). It also discloses sales by the same person during the past three months: 933, 748, 1,879 and 1,448 shares generating stated gross proceeds of $95,617; $72,114; $138,050; and $103,532 respectively. The filer certifies no undisclosed material adverse information and follows the Rule 144 notice requirements.